Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII‐A deficiency: international phase 3b trial results

Autor:	Michael Williams, Andrew M. Will, Lotte Jacobsen, Bryce A. Kerlin, Aida Inbal, May-Lill Garly, Susan L. Kearney
Rok vydání:	2017
Předmět:	Male Pediatrics medicine.medical_specialty Time Factors medicine.medical_treatment 030204 cardiovascular system & hematology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Fibrinolysis medicine Humans Factor XIII deficiency Adverse effect Congenital Bleeding Disorder Bleeding episodes Factor XIII Coagulants business.industry Head injury Age Factors Infant Hematology medicine.disease Factor XIII Deficiency Recombinant Proteins Treatment Outcome Child Preschool Female Factor XIIIa business 030215 immunology medicine.drug
Zdroj:	Journal of Thrombosis and Haemostasis. 15:1601-1606
ISSN:	1538-7836
DOI:	10.1111/jth.13748
Popis:	SummaryBackground Factor XIII deficiency is a rare, severe congenital bleeding disorder. Monthly prophylaxis with recombinant factor XIII (rFXIII) has demonstrated favorable safety and efficacy in patients ≥6 years and may similarly benefit younger children. Objective To evaluate the long-term safety and efficacy of rFXIII in children
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c6e1689196d808b9b3293d622b2225 https://doi.org/10.1111/jth.13748 Zobrazit plný text záznamu Plný text